Connor, Clark & Lunn Investment Management (CC&L)
PTX

Connor, Clark & Lunn Investment Management (CC&L)’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio PTX Stock Details PTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-15,710
Closed -$165K – 987
2016
Q1 		$165K Sell
15,710
-3,960
-20% -$78.7K ﹤0.01% 729
2015
Q4 		$580K Buy
19,670
+5,495
+39% +$166K ﹤0.01% 523
2015
Q3 		$448K Buy
14,175
+10,210
+258% +$488K ﹤0.01% 541
2015
Q2 		$235K Buy
+3,965
New +$280K ﹤0.01% 534

Other funds holding PTX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $783M AUM 81.58% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s PTX Position: Q2 2016 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q2 2016, closing a stake of 15,710 shares — an estimated $165K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in PTX in Q2 2015 and held it in 4 quarters. The position peaked at $580K in Q4 2015. 56 funds tracked by Wall St. Rank hold PTX as of Q2 2016.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q2 2016 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 15,710 Pernix Therapeutics Holdings, Inc. shares in Q2 2016, an estimated $165K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Pernix Therapeutics Holdings, Inc. in Q2 2015 and held it in 4 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Pernix Therapeutics Holdings, Inc. position peaked at $580K in Q4 2015.
  • 56 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q2 2016.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2016, filed 15 Aug 2016.